Application of PCSK9 Inhibitors in Practice-Reference-Cited by-同舟云学术

Application of PCSK9 Inhibitors in Practice

Published:2019-01-04 Issue:1 Volume:124 Page:32-37
ISSN:0009-7330
Container-title:Circulation Research
language:en
Short-container-title:Circ Res

Author:

Kaufman Tina M.¹,Warden Bruce A.¹,Minnier Jessica¹²,Miles Joshua R.¹,Duell P. Barton¹,Purnell Jonathan Q.¹,Wojcik Cezary³,Fazio Sergio¹,Shapiro Michael D.¹

Affiliation:

1. From the Center for Preventive Cardiology, Knight Cardiovascular Institute (T.M.K., B.A.W., J.M., J.R.M., P.B.D., J.Q.P., S.F., M.D.S.), Oregon Health & Science University, Portland.

2. OHSU-PSU School of Public Health (J.M.), Oregon Health & Science University, Portland.

3. Department of Family Medicine (C.W.), Oregon Health & Science University, Portland.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology

Reference25 articles.

1. Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association

2. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.;Lloyd-Jones DM;J Am Coll Cardiol,2017

3. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

4. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

5. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings;Advances in Therapy;2024-04-30

2. The impact of the 2019 ESC/EAS dyslipidaemia guidelines on real-world initial lipid-lowering therapy in patients with acute myocardial infarction;Medicine;2024-03-22

3. Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias’ treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network metaanalysis;Clínica e Investigación en Arteriosclerosis (English Edition);2024-03

4. Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature;Drugs;2024-01-25

5. The Link between miRNAs and PCKS9 in Atherosclerosis;Current Medicinal Chemistry;2023-11-16